FDG PET in the management of lymphoma: a clinical perspective (Q43933692)

28 November 2017

0 references

FDG PET in the management of lymphoma: a clinical perspective (English)

1 reference

28 November 2017

P J Hoskin

1

1 reference

28 November 2017

publication date

23 February 2002

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

28 November 2017

published in

1 reference

28 November 2017

volume

29

1 reference

28 November 2017

issue

4

1 reference

28 November 2017

page(s)

449-451

1 reference

Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-001-0755-4

2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial

21 January 2018

1 reference

12 December 2020

[Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma]

1 reference

12 December 2020

Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.

1 reference

12 December 2020

[Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment]

1 reference

12 December 2020

10.1007/S00259-001-0755-4

Identifiers

DOI

1 reference

28 November 2017

1 reference